The New York Times reports that José Baselga, chief medical officer at Memorial Sloan Kettering Cancer Center, didn't always disclose industry ties.
MSKCC investigators showed that truncated mRNAs can inactivate tumor suppressor genes, fueling cancer development even without the presence of DNA mutations.
In a pair of commentaries, researchers critique last year's paper reporting the use of CRISPR/Cas9 to correct a mutation in viable human embryos.
Stat News reports that IBM's Watson supercomputer sometimes gives inappropriate cancer treatment advice.
In Cell this week: structural variants affecting regulatory loci in prostate cancer, immune features in the breast cancer microenvironment, and more.
In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.
Researchers looked at the prevalence and effects of whole-genome duplication events across cancers using targeted sequenced data for almost 10,000 advanced cases.
Researchers analyzed germline mutations in 256 kidney cancer patients and found mutations that would have been missed, including therapeutically relevant ones.
A new analysis of immune cells in breast carcinomas and matched blood, breast, and lymph tissue uncovered phenotypic expansions in tumor immune cell populations.
In PNAS this week: alternative splicing patterns in sunflowers, EGFR inhibitor resistance in lung adenocarcinoma, and more.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.